TheraRadar
← Back
Data updated: Jun 28, 2026

ISTITUTO BIO ITA SPA

Generics

ISTITUTO BIO ITA SPA is a generic drug manufacturer focused on Infectious Disease, Dermatology, Gastroenterology.

1987
Since
7
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

ISTITUTO BIO ITA SPA's Key Drugs

ISTITUTO BIO ITA SPA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ISTITUTO BIO ITA SPA's Recent FDA Approvals

New NDA/BLA approvals for ISTITUTO BIO ITA SPA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ISTITUTO BIO ITA SPA's Therapeutic Areas

ISTITUTO BIO ITA SPA's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 57%
4 drugs
Dermatology 29%
2 drugs
Gastroenterology 14%
1 drugs

ISTITUTO BIO ITA SPA's Top Competitors

ISTITUTO BIO ITA SPA's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Pfizer, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ISTITUTO BIO ITA SPA Pipeline Snapshot

Active clinical trials for ISTITUTO BIO ITA SPA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling